帕利珠单抗可能会干扰市售的基于抗体-抗原的呼吸道合胞病毒诊断检测。
Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays.
机构信息
From the *United States Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Antimicrobial Products, Division of Antiviral Products, Silver Spring; and †MedImmune, LLC, Gaithersburg, MD.
出版信息
Pediatr Infect Dis J. 2013 Oct;32(10):1144-6. doi: 10.1097/INF.0b013e31829561dd.
Palivizumab is a monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus infection in infants. The potential for palivizumab to interfere with commercially available respiratory syncytial virus diagnostic tests was demonstrated. Negative test results in palivizumab-treated subjects should be interpreted with caution and confirmed by a nucleic acid amplification-based assay.
帕利珠单抗是一种单克隆抗体，用于预防呼吸道合胞病毒感染引起的婴儿严重下呼吸道疾病。帕利珠单抗具有干扰市售呼吸道合胞病毒诊断检测的潜力。在接受帕利珠单抗治疗的患者中，阴性检测结果应谨慎解读，并通过基于核酸扩增的检测方法进行确认。
Zotero 插件